Chemistry and Life

Medicinal chemistry. Pharmacology. Toxicology. Environmental sciences.

Idelalisib, a phosphoinositide 3-kinase (PI3K) inhibitor

1 Comment

From Wikimedia CommonsThis paper in the New England Journal of Medicine describes encouraging clinical results for idelalisib (in combination with the existing drug rituximab) for the treatment of leukemia.  Idelalisib is an inhibitor of phosphoinositide 3-kinase (PI3K), a target that has been of high interest in oncology drug discovery in recent years.  There is a lot of time and effort invested in this target with many pharmaceutical companies pursuing this line of research and development.  Idelalisib, as far as I am aware, is furthest along in clinical development so it is definitely good news to have this kind of positive validation in late stage clinical trials.


One thought on “Idelalisib, a phosphoinositide 3-kinase (PI3K) inhibitor

  1. Fantastic website. A lot of useful info here. I am sending it to some buddies ans additionally sharing in delicious. And of course, thanks to your effort!

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s